"These results were highly significant. But more importantly, the data suggested a subgroup where the big bang for the buck was," Dr. Cooper said in the interview.
The findings don’t mean that the patients who did not benefit are not "high risk," Dr. Cooper said. "Would they benefit from other chemotherapy? We don’t know. Would they benefit from different drugs or different regimens? Maybe. But we can now fairly comfortably say that in both the short and long run, if patients are high risk only because of involved lymph nodes, don’t treat them with this combination, and spare them the toxicity."
Dr. Cooper stated that he has no disclosures, as did nine coauthors. One additional coauthor is an employee of Lilly USA.